var data={"title":"Treatment of drug-resistant pulmonary tuberculosis in adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of drug-resistant pulmonary tuberculosis in adults</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributors\" class=\"contributor contributor_credentials\">Neil W Schluger, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributors\" class=\"contributor contributor_credentials\">Scott K Heysell, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributors\" class=\"contributor contributor_credentials\">Gerald Friedland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Diagnosis, treatment, and prevention of TB has become more complex because of resistance to commonly used antituberculous drugs. (See <a href=\"topic.htm?path=epidemiology-and-molecular-mechanisms-of-drug-resistant-tuberculosis\" class=\"medical medical_review\">&quot;Epidemiology and molecular mechanisms of drug-resistant tuberculosis&quot;</a>.)</p><p>Management of drug-resistant TB can be difficult and may necessitate use of second-line drugs <span class=\"nowrap\">and/or</span> surgical resection. Management of such patients should be undertaken by individuals with expertise in this area or in very close consultation with such individuals, in the context of a supportive public health infrastructure [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Good patient outcomes depend upon rapid and accurate diagnosis together with administration of proper therapy with close monitoring to assure adherence to the treatment regimen and patient safety.</p><p>Issues related to treatment of drug-resistant TB<em> </em>are reviewed here. Issues related to treatment of drug-susceptible TB are discussed separately, as are issues related to interactions between second-line TB drugs and antiretroviral therapy in HIV-infected individuals. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Definitions to describe the different types of drug-resistant tuberculosis include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;drug-resistant tuberculosis&quot; refers to TB caused by an isolate of <em>Mycobacterium tuberculosis</em> that is resistant to one or more antituberculous drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;monoresistant TB&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to a single antituberculous agent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;poly-resistant TB&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to more than one antituberculous agent; the isolate may be resistant to either <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> or <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> but not both.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;multidrug-resistant TB&quot; (MDR-TB) refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to both <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and possibly additional agents [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;extensively drug-resistant TB&quot; (XDR-TB) refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to at least <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and fluoroquinolones as well as either aminoglycosides (<a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a>, <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>) or <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">capreomycin</a> or both [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=epidemiology-of-extensively-drug-resistant-tuberculosis#H2\" class=\"medical medical_review\">&quot;Epidemiology of extensively drug-resistant tuberculosis&quot;, section on 'Definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;totally drug-resistant TB&quot; (TDR-TB) refers to an isolate of <em>M. tuberculosis</em> resistant to all locally tested medications [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/6,7\" class=\"abstract_t\">6,7</a>]. However, the published studies initially describing TDR-TB did not include susceptibility testing for less frequently used agents with activity against TB (including <a href=\"topic.htm?path=cycloserine-drug-information\" class=\"drug drug_general\">cycloserine</a>, terizidone, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, or carbapenems) or more recently introduced agents (including <a href=\"topic.htm?path=bedaquiline-drug-information\" class=\"drug drug_general\">bedaquiline</a> and delamanid). (See <a href=\"topic.htm?path=epidemiology-of-extensively-drug-resistant-tuberculosis#H2\" class=\"medical medical_review\">&quot;Epidemiology of extensively drug-resistant tuberculosis&quot;, section on 'Definitions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary drug resistance refers to infection caused by a drug-resistant strain of <em>M. tuberculosis</em> contracted in the absence of previous antituberculous therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Secondary drug resistance refers to the development of drug resistance during or following antituberculous therapy in patients who had previously had drug-susceptible TB and have not been reinfected by a different drug-resistant organism.</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations and radiographic features of drug-resistant tuberculosis (TB) are comparable with those of drug-susceptible TB. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p>The most important predictors of drug-resistant TB are [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2,8\" class=\"abstract_t\">2,8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A previous episode of TB treatment</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistent or progressive clinical <span class=\"nowrap\">and/or</span> radiographic findings while on TB therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Residence in or travel to a region with high prevalence of drug-resistant TB</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to an individual with known or suspected infectious drug-resistant TB</p><p/><p>Additional risk factors associated with development of drug-resistant TB are summarized in the table (<a href=\"image.htm?imageKey=ID%2F108729\" class=\"graphic graphic_table graphicRef108729 \">table 1</a>) and are discussed further separately. (See <a href=\"topic.htm?path=epidemiology-and-molecular-mechanisms-of-drug-resistant-tuberculosis#H10\" class=\"medical medical_review\">&quot;Epidemiology and molecular mechanisms of drug-resistant tuberculosis&quot;, section on 'Risk factors for development of drug resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H3816513493\"><span class=\"h1\">EMPIRIC TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to start an expanded empiric treatment regimen for drug-resistant tuberculosis (TB; a regimen including second-line drugs) pending conventional, culture-based drug susceptibility data depends on the severity of clinical illness and the degree of suspicion for drug-resistant tuberculosis (given epidemiologic factors <span class=\"nowrap\">and/or</span> results of acid-fast bacilli [AFB] smear and nucleic acid amplification [NAA] testing).</p><p>Patients for whom an expanded empiric treatment regimen may be warranted include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with treatment failure (AFB sputum culture positive after four months of therapy)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with relapse (recurrent TB after prior completion of treatment with apparent cure)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with exposure to an individual with drug-resistant TB</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with residence in or travel to a region with high prevalence of drug-resistant tuberculosis</p><p/><p>It may be reasonable to defer treatment until drug susceptibility results are available for patients who are not severely ill and can be isolated if potentially infectious, particularly for circumstances in which few remaining treatment options are available.</p><p>An expanded empiric regimen usually consists of first-line drugs (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>) plus two or more additional drugs. Severe systemic infection (such as meningitis or miliary disease) should prompt addition of at least three additional drugs. These additional drugs include a fluoroquinolone, an injectable agent, <span class=\"nowrap\">and/or</span> another core second-line agent (<a href=\"image.htm?imageKey=ID%2F83653\" class=\"graphic graphic_table graphicRef83653 \">table 2</a>). A single drug should never be added to a failing regimen, as this may lead to acquired resistance to the new drug.</p><p>The choice of second-line drugs should reflect the prior treatment history, the drug resistance pattern of the source case (if available), the likely patterns of resistance in the patient's region of origin, and, if available, results of molecular testing of the isolate for drug resistance. The regimen should be chosen in consultation with an individual who has expertise with treatment of drug-resistant tuberculosis and should be administered with directly observed therapy.</p><p>The regimen should be adjusted accordingly once drug susceptibility results are available, as discussed in the following sections.</p><p>Drug dosing is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>).</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">TREATMENT OF MONORESISTANT TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical approach to treatment of monoresistant tuberculosis (TB) varies depending on the agent to which the isolate is resistant. In general, the approach to selection of antituberculous therapy is similar for HIV-uninfected and HIV-infected patients, although many favor extending the duration of therapy for HIV-infected patients by approximately three months.</p><p>Drug dosing is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>).</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Isoniazid monoresistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to treatment of patients with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (INH)-monoresistant TB is generally based on expert opinion informed by retrospective or single-arm studies.</p><p>Options for treatment of patients with known INH-monoresistant TB include [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Option 1</strong>: Daily <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> (with or without a fluoroquinolone) for six to nine months (or four months after culture conversion) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/9\" class=\"abstract_t\">9</a>]; in HIV-infected patients, it is reasonable to prolong therapy for an additional three months [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/10-12\" class=\"abstract_t\">10-12</a>].</p><p/><p class=\"bulletIndent1\">This approach is based on trials conducted by the Hong Kong Chest <span class=\"nowrap\">Service/British</span> Medical Research Council, which demonstrated success rates of 95 to 98 percent among 107 patients with INH-resistant disease [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/13\" class=\"abstract_t\">13</a>]. It is also supported by a retrospective study of patients with INH-monoresistant TB treated for six months; rates of treatment failure or relapse were comparable with patients with drug-susceptible TB [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/12\" class=\"abstract_t\">12</a>], although for many patients the duration of therapy was extended because <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> was not administered for the entire six months initially.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Option 2</strong>: If the patient does not tolerate <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, a regimen consisting of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, and a fluoroquinolone for 9 to 12 months may be used; fluoroquinolone susceptibility should be confirmed [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p>For treatment of patients for whom drug susceptibility testing is not available but who are known to reside in a region with a background level of INH resistance &gt;7 percent, an acceptable approach consists of a standard intensive phase (eg, <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>), followed by continuation phase consisting of isoniazid and rifampin with addition of ethambutol (rather than isoniazid and rifampin alone) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/15,16\" class=\"abstract_t\">15,16</a>]. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p>Effective therapy for INH-monoresistant TB is associated with very high bacteriologic and clinical response rates (&gt;95 percent) and low relapse rates (&lt;5 percent) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/12,17\" class=\"abstract_t\">12,17</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Monoresistance to other agents</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> &ndash; Patients with rifampin monoresistance should be treated as for multidrug-resistant TB, in accordance with World Health Organization guidelines issued in 2016 [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H12\" class=\"local\">'Treatment of multidrug-resistant TB'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">Pyrazinamide</a> &ndash; Patients with pyrazinamide monoresistance should be treated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> for nine months. This combination has a success rate &gt;96 percent in large trials [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Many isolates with pyrazinamide monoresistance reflect <em>M. bovis</em> disease. (See <a href=\"topic.htm?path=mycobacterium-bovis\" class=\"medical medical_review\">&quot;Mycobacterium bovis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other agents</strong> &ndash; Monoresistance to <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">streptomycin</a>, or second-line agents is of little clinical significance; patients with disease caused by these isolates may be treated as for drug-susceptible TB (intensive phase: <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and ethambutol [if not resistant] for two months; followed by continuation phase: isoniazid and rifampin for four months). (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4285597129\"><span class=\"h1\">TREATMENT OF POLY-RESISTANT TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;poly-resistant tuberculosis (TB)&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to more than one antituberculous agent; the isolate may be resistant to either <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> or <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> but not both. (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above.)</p><p>Treatment of poly-resistant TB depends on the pattern of drug resistance; in general, it should include as many first-line agents as possible plus a fluoroquinolone and, in some cases, an injectable drug. Suggested regimens are summarized in the table (<a href=\"image.htm?imageKey=ID%2F108731\" class=\"graphic graphic_table graphicRef108731 \">table 5</a>).</p><p>Drug dosing is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>).</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">TREATMENT OF MULTIDRUG-RESISTANT TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;multidrug-resistant tuberculosis (MDR-TB)&quot; refers to an isolate of <em>M. tuberculosis</em> that is resistant to both <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and possibly additional agents. (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above.)</p><p>The treatment approach discussed below is warranted for patients with MDR-TB or rifampin-monoresistant TB. Regimens should be chosen in consultation with an individual who has expertise with treatment of MDR-TB whenever possible.</p><p>In addition, consideration of surgery is warranted under specific circumstances. (See <a href=\"#H3057034217\" class=\"local\">'Role of surgery for MDR- or XDR-TB'</a> below.)</p><p class=\"headingAnchor\" id=\"H1101222462\"><span class=\"h2\">Clinical approach</span></p><p class=\"headingAnchor\" id=\"H1543255266\"><span class=\"h3\">Nonpregnant adults</span></p><p class=\"headingAnchor\" id=\"H2010335105\"><span class=\"h4\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to treatment of MDR-TB depends on results of drug susceptibility testing (DST) and availability of antituberculous agents. Management of MDR-TB cases should be supervised by medical personnel with expertise and experience in administering complicated antituberculous regimens, in conjunction with appropriate laboratory facilities to document drug susceptibility and to monitor patient safety and response to therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Antituberculous drugs that may be used for treatment of MDR-TB are summarized in the table (<a href=\"image.htm?imageKey=ID%2F83653\" class=\"graphic graphic_table graphicRef83653 \">table 2</a>). Dosing for antituberculous drug agents is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>). Issues related to individual antituberculous agents are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;</a>.)</p><p>In general, the optimal number of drugs, combination of drugs, and duration of therapy for treatment of MDR-TB are uncertain. Options for treatment of MDR-TB include the conventional MDR treatment regimen (total duration of therapy generally 20 to 26 months) or a shortened regimen (total duration of therapy 9 to 12 months).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Conventional regimen &ndash; The conventional regimen (total duration 20 to 26 months) for treatment of MDR-TB consists of an intensive phase (administration of at least <strong>five</strong> effective drugs including an injectable drug) for at least 6 months after sputum culture conversion, followed by a continuation phase (administration of at least <strong>four</strong> effective drugs in the absence of an injectable drug) for an additional 12 months, providing at least 18 months of treatment beyond sputum culture conversion [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>]. A single drug should never be added to a failing regimen, as this may lead to acquired resistance to the new drug.</p><p/><p class=\"bulletIndent1\">Support for this approach comes from a retrospective cohort study including 668 Peruvian patients who started an individualized MDR-TB regimen. Regimens of four likely effective drugs were associated with higher mortality rates than regimens with five likely effective drugs (adjusted hazard ratio [HR] 2.87, 95% CI 1.35-6.09, versus adjusted HR 2.76, 95% CI 0.92-8.27) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/22\" class=\"abstract_t\">22</a>]. In addition, the mortality rate for regimens of five likely effective drugs with likely effective <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> (PZA) was similar to that for the regimen of five likely effective drugs without PZA (HR 1.00, 95% CI 0.12-8.00).</p><p/><p class=\"bulletIndent1\">The conventional regimen is discussed in greater detail below. (See <a href=\"#H2784291708\" class=\"local\">'Conventional regimen'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Shortened regimen &ndash; The shortened regimen (total duration 9 to 12 months) is appropriate for nonpregnant patients with MDR-TB (in the absence of extrapulmonary disease), with an isolate known to be susceptible to fluoroquinolones and injectable antituberculous agents and with no prior exposure to second-line agents for more than one month [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>]. Patients with known or suspected MDR-TB who do not meet criteria for the shortened MDR-TB regimen should be treated with the conventional regimen.</p><p/><p class=\"bulletIndent1\">The shortened regimen is discussed in greater detail below. (See <a href=\"#H2244677597\" class=\"local\">'Shortened regimen'</a> below.)</p><p/><p>Design of the treatment regimen can be difficult and must take into account several factors [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug susceptibility test results.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-resistance (which occurs among fluoroquinolones, among injectable agents, between <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a>, and between <a href=\"topic.htm?path=bedaquiline-drug-information\" class=\"drug drug_general\">bedaquiline</a> and <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior use of antituberculous agents; patients who have taken a drug for longer than one month have less effect from that drug, even if in vitro testing demonstrates susceptibility. Nonetheless, most favor inclusion of first-line drugs with documented susceptibility in the regimen, though some may choose not to count previously used drugs as one of the target effective drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adverse effects and drug toxicity.</p><p/><p>All patients with drug-resistant TB should be assigned to a clinical case manager who oversees all aspects of the patient's care (medical and social) and provides supervised treatment (directly observed therapy [DOT]) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/23,24\" class=\"abstract_t\">23,24</a>]. Adherence to MDR-TB therapy is particularly difficult because regimens are prolonged and employ drugs with considerable adverse effects. (See <a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">&quot;Adherence to tuberculosis treatment&quot;</a>.)</p><p>Repeat sputum should be obtained for acid-fast bacilli (AFB) microscopy and culture two months after initiation of therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1,2\" class=\"abstract_t\">1,2</a>]. If positive, the sputum evaluation should be repeated monthly until negative and the duration of the intensive phase should continue until at least six months after sputum culture conversion.</p><p>Treatment regimens should be tailored once drug susceptibility data are available. If full drug susceptibility is documented, the patient does not have drug-resistant TB; the additional drugs may be discontinued and treatment may be completed with a standard regimen. If MDR-TB is documented, drugs to which the isolate is resistant should be discontinued, and new drugs should be added such that at least four drugs active against the most prevalent drug-resistant strains are included in the regimen based on the sequence outlined above. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H333119688\"><span class=\"h4\">Regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conventional and shortened regimens for treatment of MDR-TB are described in the following sections.</p><p class=\"headingAnchor\" id=\"H2784291708\"><span class=\"h5\">Conventional regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, patients with known or suspected MDR-TB (infection acquired in area with high prevalence of MDR-TB or infection following contact with an individual known to have MDR-TB) should be treated with the conventional regimen (total duration of therapy 20 to 26 months).</p><p>An empiric conventional regimen consists of the following [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1,2,25,26\" class=\"abstract_t\">1,2,25,26</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An intensive phase consisting of at least <strong>five drugs</strong> &ndash; Susceptible first-line drugs if any (<a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>), a fluoroquinolone, an injectable agent, and one or more additional oral second-line agents (<a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a>, <a href=\"topic.htm?path=cycloserine-drug-information\" class=\"drug drug_general\">cycloserine</a>, <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a>, or <a href=\"topic.htm?path=para-aminosalicylic-acid-aminosalicylate-drug-information\" class=\"drug drug_general\">para-aminosalicylic acid</a>) given for at least <strong>six months</strong> beyond sputum culture conversion (performed after two months of treatment). If there are not at least five active drugs available in these categories, add-on agents include high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, <a href=\"topic.htm?path=bedaquiline-drug-information\" class=\"drug drug_general\">bedaquiline</a>, delamanid, and a carbapenem (<a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> or <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>) plus clavulanate (<a href=\"image.htm?imageKey=ID%2F113635\" class=\"graphic graphic_table graphicRef113635 \">table 6</a> and <a href=\"image.htm?imageKey=ID%2F113634\" class=\"graphic graphic_figure graphicRef113634 \">figure 1</a>). (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2739502074\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Second-line agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A continuation phase consisting of the drugs used during the intensive phase with the exception of the injectable agent, given for <strong>18 to 24 months</strong> beyond sputum culture conversion (performed after two months of treatment). Patients with extensive disease or cavitary disease may warrant a longer duration for the injectable drug <span class=\"nowrap\">and/or</span> use of an additional oral second-line drug. Patients who have received prior treatment with <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> or <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> may also warrant an additional oral second-line drug.</p><p/><p>The World Health Organization (WHO) favors empiric addition of high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (15 to 20 <span class=\"nowrap\">mg/kg/day)</span> to the above regimens [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Regimens should be tailored to the drug susceptibility results when available and to drug side effects and toxicities.</p><p>General principles related to directly observed therapy, follow-up sputum examination, and tailoring treatment regimens are discussed above. (See <a href=\"#H2010335105\" class=\"local\">'General principles'</a> above.)</p><p class=\"headingAnchor\" id=\"H2244677597\"><span class=\"h5\">Shortened regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The shortened MDR-TB regimen for pulmonary tuberculosis (total duration of therapy 9 to 11 months) was described by the WHO in 2016 [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>]; it is appropriate for nonpregnant patients with MDR-TB who meet the following criteria:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of extrapulmonary disease</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Access to all component antituberculous drugs in the regimen: <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a>, <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>, prothionamide, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No resistance to the drugs in the regimen (except <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> resistance)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No previous exposure to drugs in the regimen for more than one month</p><p/><p>Patients with MDR-TB who are candidates for treatment with a shortened treatment regimen may be identified using the MTBDR<em>sl</em> assay; the WHO has advocated use of this assay as the initial test for detection of resistance to fluoroquinolones and second-line injectable drugs. The MTBDR<em>sl</em> assay does not test for resistance to <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a> and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, predicts most but not all resistance to <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a> and the fluoroquinolones (compared with phenotypic culture-based testing), and predicts <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> resistance less reliably [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/27\" class=\"abstract_t\">27</a>]. The MTBDR<em>sl</em> assay is not approved by the US Food and Drug Administration and is not routinely available in the United States unless validated by the testing laboratory [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults#H4154933816\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;, section on 'Probe-based (NAA) tests'</a>.)</p><p>The implementation of the shortened regimen is challenging in the absence of access to rigorous drug-susceptibility testing for all drugs in the regimen [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/29\" class=\"abstract_t\">29</a>]. Accordingly, drug-susceptibility should be scaled up to meet local needs in conjunction with introduction of any novel antibiotic regimen. In addition, the shortened regimen may not be applicable in certain regions of the world (such as countries of the former Soviet Union), where there are many patients with previous treatment for TB and MDR-TB is common [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/30,31\" class=\"abstract_t\">30,31</a>].</p><p>In the United States, some experts favor use of the shortened regimen for patients with MDR-TB and minimal radiographic disease or low bacillary burden [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2\" class=\"abstract_t\">2</a>].</p><p>The shortened regimen consists of the following components:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intensive phase &ndash; Four months (daily) of seven drugs: high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (15 to 20 <span class=\"nowrap\">mg/kg/day),</span> <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a>, <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>, prothionamide, and <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>. The duration of the intensive phase is extended to six months for patients with positive sputum AFB microscopy and culture performed two months after initiation of therapy. (See <a href=\"#H2010335105\" class=\"local\">'General principles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Continuation phase &ndash; Five months (daily) of four drugs: <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a>, and <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>.</p><p/><p>General principles related to directly observed therapy, follow-up sputum examination, and tailoring treatment regimens are discussed above. (See <a href=\"#H2010335105\" class=\"local\">'General principles'</a> above.)</p><p>The shorter MDR-TB regimen advocated by the WHO is based in part on reported success with a &quot;nine-month Bangladesh regimen&quot; consisting of nine months of treatment with <a href=\"topic.htm?path=gatifloxacin-drug-information\" class=\"drug drug_general\">gatifloxacin</a>, <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>, <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, supplemented in the first four months by <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>, prothionamide, and high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/32\" class=\"abstract_t\">32</a>]. If sputum smears were still positive at four months, the intensive phase was continued until smears were negative, and the continuation phase was fixed at an additional five months. DOT was used throughout. Among 515 patients, bacteriologically favorable outcomes were achieved in 84 percent of cases. The strongest predictor of failure was the presence of high-level fluoroquinolone resistance. Because of slow response to therapy, only half of the patients could complete treatment within 9 months, but 95 percent completed within 12 months, a significantly shorter time than required for most other recommended regimens.</p><p class=\"headingAnchor\" id=\"H1802415633\"><span class=\"h4\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patient education regarding symptoms of hepatitis and other possible drug toxicities should be reviewed with the patient at each DOT visit and reinforced at each clinic visit. Patients should be instructed to report signs or symptoms of toxicity to their provider immediately and stop medications until advised to resume treatment. Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p>During treatment, sputum should be obtained for AFB smear and culture and drug susceptibility testing at monthly intervals until two consecutive cultures are negative [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/10\" class=\"abstract_t\">10</a>]. Following two successive months of negative sputum cultures, repeat culture and drug susceptibility testing are usually reserved only for persistent or worsening symptoms despite adequate adherence to therapy.</p><p>In patients with extensive pulmonary disease, monthly or biweekly chest radiographs may also be monitored to gauge for radiographic signs of further treatment failure <span class=\"nowrap\">and/or</span> to prompt consideration of adjunctive surgery.</p><p class=\"headingAnchor\" id=\"H3138981029\"><span class=\"h3\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of children with MDR-TB is discussed further separately. (See <a href=\"topic.htm?path=tuberculosis-disease-in-children#H23631564\" class=\"medical medical_review\">&quot;Tuberculosis disease in children&quot;, section on 'Drug-resistant TB'</a>.)</p><p class=\"headingAnchor\" id=\"H3145613949\"><span class=\"h3\">Pregnant women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to treatment of pregnant women with MDR-TB is uncertain. In general, the approach to selection of antituberculous agents is similar to the conventional MDR-TB regimen for nonpregnant adults. Data are insufficient for use of the shortened MDR-TB regimen in pregnant women. (See <a href=\"#H333119688\" class=\"local\">'Regimens'</a> above.)</p><p><a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">Pyrazinamide</a> is usually excluded from treatment of drug-susceptible TB during pregnancy in the United States, although it is used elsewhere. There are no controlled data on the use of pyrazinamide in pregnancy, and its use in pregnant women with drug-resistant disease is justifiable for circumstances in which drug choice is limited and benefit outweighs risk [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Antituberculous agents that are not considered safe in pregnancy include injectable agents, <a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a>, and prothionamide. In one case series describing the long-term follow-up of six children with intrauterine exposure to second-line agents during treatment of MDR-TB during pregnancy, there was no evidence of significant toxicity among the children (average age at follow-up 3.7 years); one child was diagnosed with MDR-TB [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/33\" class=\"abstract_t\">33</a>].</p><p>The experience with treatment of MDR-TB in pregnancy is limited; data from Peru have demonstrated that birth outcomes among pregnant women treated for MDR-TB are comparable with outcomes among nonpregnant individuals [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H3115947\"><span class=\"h3\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment failure refers to positive cultures after four months of antituberculous therapy. Treatment failure should raise concern for resistance to drugs in the regimen being administered at the time when failure is diagnosed. Treatment failure in the setting of drug-resistant TB likely reflects relatively weak potency of second-line antituberculous drugs.</p><p>A new treatment regimen should be developed based on drug susceptibility testing results, together with careful review of previous medications and adherence [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/10\" class=\"abstract_t\">10</a>]. Any agent taken for more than one month is likely to have decreased efficacy. Patients with treatment failure should receive highest priority for directly observed therapy.</p><p>An empiric retreatment regimen should include at least four drugs likely to be effective. This usually entails use of a regimen with greater toxicity than the prior regimen.</p><p>Therapeutic drug-level monitoring may be useful in patients who do not respond to a seemingly appropriate regimen administered with directly observed therapy and has been used routinely at the initiation of therapy in some centers [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/35,36\" class=\"abstract_t\">35,36</a>]. Low serum levels of anti-TB drugs have been reported in patients with malabsorption and in some individuals with HIV infection (even in the absence of clinical malabsorption) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/37,38\" class=\"abstract_t\">37,38</a>]. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H1618032856\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Serum drug concentration monitoring'</a>.)</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment success rates for MDR-TB range from 30 to 80 percent; factors associated with treatment success include [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/4,39-46\" class=\"abstract_t\">4,39-46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of therapy at least 18 months</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Directly observed therapy throughout treatment</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical resection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluoroquinolone use</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No previous treatment</p><p/><p>Factors associated with unfavorable outcomes include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Male gender</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alcohol abuse</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of weight gain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Smear positivity at diagnosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluoroquinolone resistance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIV coinfection</p><p/><p class=\"headingAnchor\" id=\"H4264781502\"><span class=\"h1\">TREATMENT OF EXTENSIVELY DRUG-RESISTANT TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;extensively drug-resistant tuberculosis (XDR-TB)&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to at least <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and fluoroquinolones as well as either aminoglycosides (<a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a>, <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>) or <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">capreomycin</a> or both. (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above.)</p><p>Regimens should be chosen in consultation with an individual who has expertise with treatment of multidrug-resistant tuberculosis (MDR-TB) whenever possible and in collaboration with the jurisdictional public health program. (See <a href=\"#H3445015247\" class=\"local\">'Resources for expert guidance'</a> below.)</p><p>In addition, consideration of surgery is warranted under specific circumstances. (See <a href=\"#H3057034217\" class=\"local\">'Role of surgery for MDR- or XDR-TB'</a> below.)</p><p class=\"headingAnchor\" id=\"H1915663590\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to treatment of XDR-TB depends on results of drug susceptibility testing (DST) and availability of antituberculous agents. Management of XDR-TB cases should be supervised by medical personnel with expertise and experience in administering complicated antituberculous regimens, in conjunction with appropriate laboratory facilities to document drug susceptibility and to monitor patient safety and response to therapy.</p><p>Antituberculous drugs that may be used for treatment of XDR-TB are summarized in the table (<a href=\"image.htm?imageKey=ID%2F83653\" class=\"graphic graphic_table graphicRef83653 \">table 2</a>). Dosing for antituberculous drug agents is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>). Issues related to individual antituberculous agents are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;</a>.)</p><p>The approach to selecting antituberculous drugs for treatment of XDR-TB is as follows (<a href=\"image.htm?imageKey=ID%2F113635\" class=\"graphic graphic_table graphicRef113635 \">table 6</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2,3,47-50\" class=\"abstract_t\">2,3,47-50</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An intensive phase consisting of at least <strong>six drugs</strong> &ndash; Susceptible first-line drugs if any (<a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>), a fluoroquinolone (preferably high-dose <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a>), an injectable agent (preferably <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">capreomycin</a>), and one or more additional oral agents (preferably <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> and either <a href=\"topic.htm?path=bedaquiline-drug-information\" class=\"drug drug_general\">bedaquiline</a> or delamanid; additional options include <a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a>, <a href=\"topic.htm?path=cycloserine-drug-information\" class=\"drug drug_general\">cycloserine</a>, <a href=\"topic.htm?path=para-aminosalicylic-acid-aminosalicylate-drug-information\" class=\"drug drug_general\">para-aminosalicylic acid</a>, high-dose <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">clofazimine</a>, or a carbapenem [<a href=\"topic.htm?path=meropenem-drug-information\" class=\"drug drug_general\">meropenem</a> or <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>] plus clavulanate) given for at least six months beyond sputum culture conversion (performed after two months of treatment). (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2739502074\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Second-line agents'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A continuation phase consisting of the drugs used during the intensive phase with the exception of the injectable agent, given for 18 to 24 months beyond culture conversion (performed after two months of treatment). Patients with extensive disease or cavitary disease may warrant a longer duration for the injectable drug <span class=\"nowrap\">and/or</span> use of an additional oral second-line drug. Patients who have received prior treatment with <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> or <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a> may also warrant an additional oral second-line drug.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If susceptibility to the injectable agent is confirmed and the drug is tolerated, the intensive phase (six drugs including the injectable agent) should be extended from 6 months to 12 months, and the continuation phase may be reduced accordingly to 12 to 18 months (from 18 to 24 months).</p><p/><p class=\"headingAnchor\" id=\"H572632094\"><span class=\"h2\">Outcomes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall prognosis for adults with XDR-TB is poor with high mortality; delays in diagnosis, malnutrition, and level of immunosuppression contribute to an increased risk of death [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/51,52\" class=\"abstract_t\">51,52</a>].</p><p>Among HIV-uninfected patients, survival rates for XDR-TB range from 48 to 60 percent in cohorts from South Korea, Russia, and Peru [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/47,53,54\" class=\"abstract_t\">47,53,54</a>].</p><p>Most studies suggest that HIV status correlates with poorer outcomes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In XDR-TB cases reported from the United States, there was an overall 35 percent mortality, but mortality was 81 percent in the subset of HIV-infected patients [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/55\" class=\"abstract_t\">55</a>]. However, many of these occurred before the availability of potent antiretroviral therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the original case series from Tugela Ferry, South Africa, the mortality rate among those identified with both HIV and XDR-TB infection was 98 percent [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/56\" class=\"abstract_t\">56</a>]. In subsequent analysis of 139 patients with XDR-TB, 80 percent died. Factors significantly associated with mortality included CD4 count &le;50 <span class=\"nowrap\">cells/mm<sup>3</sup></span> and resistance to all six anti-TB drugs tested; use of antiretroviral therapy (ART) was protective [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/57\" class=\"abstract_t\">57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 227 patients with XDR-TB in South Africa (82 of whom were HIV infected), the number of deaths did not differ significantly between HIV-infected and HIV-uninfected patients (41 percent versus 30 percent); ART use (mostly <a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">zidovudine</a>, <a href=\"topic.htm?path=lamivudine-drug-information\" class=\"drug drug_general\">lamivudine</a>, and <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>) was protective [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a cohort including 107 patients with XDR-TB in South Africa (41 percent of whom were HIV infected), at 60 months of follow-up, 73 percent had died, 4 percent defaulted, 10 percent failed treatment, and only 11 percent had a favorable outcome; use of antiretroviral therapy was an independent predictor of survival [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"headingAnchor\" id=\"H2764093192\"><span class=\"h1\">HIV-INFECTED PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General issues related to treatment of tuberculosis (TB) in HIV-infected patients are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p>The approach to selection of antituberculous drugs for HIV-infected patients with monoresistant or polyresistant TB is as described above. (See <a href=\"#H7\" class=\"local\">'Treatment of monoresistant TB'</a> above and <a href=\"#H4285597129\" class=\"local\">'Treatment of poly-resistant TB'</a> above.)</p><p>The approach to selection of antituberculous drugs for HIV-infected patients with multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant tuberculosis (XDR-TB) is as described above for treatment of XDR-TB [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/3\" class=\"abstract_t\">3</a>]. If the patient is able to tolerate medication, treatment should be administered for 24 months beyond sputum culture conversion. After the cessation of therapy, patients should be examined every four months for an additional 24 months to monitor for evidence of relapse. (See <a href=\"#H4264781502\" class=\"local\">'Treatment of extensively drug-resistant TB'</a> above.)</p><p>For patients not yet on antiretroviral therapy (ART), diagnosis of TB warrants initiation of ART; the approach to timing depends on the patient's immune status. Early initiation of ART and integration of HIV and TB care are important management issues; failure to administer ART in patients with drug-resistant TB has been associated with higher mortality rates [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/52,59\" class=\"abstract_t\">52,59</a>]. Issues related to timing of ART are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p>Studies are needed to clarify the pharmacokinetic and pharmacodynamic interactions between antiretroviral agents and second-line agents for drug-resistant TB [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/60\" class=\"abstract_t\">60</a>]. Notable toxicities and potential drug interactions include (<a href=\"image.htm?imageKey=ID%2F53563\" class=\"graphic graphic_table graphicRef53563 \">table 7</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuropsychiatric effects associated with <a href=\"topic.htm?path=cycloserine-drug-information\" class=\"drug drug_general\">cycloserine</a> and <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> use</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peripheral neuropathy associated with both <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> and aminoglycosides and the rarely used nucleoside reverse transcriptase inhibitors, <a href=\"topic.htm?path=stavudine-drug-information\" class=\"drug drug_general\">stavudine</a> and <a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">didanosine</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal side effects, which are common with many protease inhibitors and many of the second-line agents for TB (eg, fluoroquinolones, <a href=\"topic.htm?path=ethionamide-drug-information\" class=\"drug drug_general\">ethionamide</a>, and <a href=\"topic.htm?path=para-aminosalicylic-acid-aminosalicylate-drug-information\" class=\"drug drug_general\">para-aminosalicylic acid</a>) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/61\" class=\"abstract_t\">61</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nephrotoxicity associated with tenofovir and aminoglycosides</p><p/><p>The integrase strand inhibitor class of antiretrovirals may be most compatible with second-line anti-TB drugs.</p><p>The importance of early institution of ART in coinfected patients was demonstrated in a substudy of the SAPiT trial, in which ART delay (associated with mortality rate of 56 per 100 person-years) was reduced to 11 per 100 person-years (an 86 percent reduction) when ART was introduced early [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/59\" class=\"abstract_t\">59</a>].</p><p class=\"headingAnchor\" id=\"H3057034217\"><span class=\"h1\">ROLE OF SURGERY FOR MDR- OR XDR-TB</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, surgery for treatment of tuberculosis is most effective for patients with poor clinical response or intolerance to supervised medical therapy who have pulmonary disease that is amenable to complete resection (lobectomy, wedge resection, or pneumonectomy) [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/62\" class=\"abstract_t\">62</a>]. Consideration of surgery for management of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is warranted in the following circumstances [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/2,47,62-70\" class=\"abstract_t\">2,47,62-70</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistently positive sputum cultures beyond four to six months of antituberculous therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of extensive drug resistance that is unlikely to be cured with antituberculous therapy alone</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of complications such as massive hemoptysis or persistent bronchopleural fistula</p><p/><p>In general, surgery should be performed only after several months of antituberculous therapy have been administered, after smear conversion (if possible), and ideally after culture conversion. Ideally, the surgical team should have extensive experience in surgical treatment of tuberculosis. A full course of antituberculous therapy should be administered following surgical resection; the date of surgery may be considered the date of culture conversion if there are no subsequent positive sputum cultures.</p><p class=\"headingAnchor\" id=\"H3445015247\"><span class=\"h1\">RESOURCES FOR EXPERT GUIDANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, expert guidance can be obtained through the Centers for Disease Control and Prevention's network of <a href=\"https://www.cdc.gov/tb/education/rtmc/&amp;token=R4Uiw8/bmPVaqNHRDqpXLLwB/MdRGhYuDEMsjmkm6wRSLSlwqTtKzAhHD9j/7tsw&amp;TOPIC_ID=8028\" target=\"_blank\" class=\"external\">Regional Training and Medical Consultation Centers</a>. These centers provide timely expert consultation on management of drug-resistant tuberculosis (TB).</p><p>The European Respiratory Society and the World Health Organization support a TB Consilium, a confidential and online consultation service for physicians caring for patients with complex multidrug-resistant or extensively drug-resistant tuberculosis or HIV coinfection [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/71\" class=\"abstract_t\">71</a>]. The TB Consilium provides access to experts with answers delivered within a week in English or Russian language [<a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H786782680\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of tuberculosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3118802\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;drug-resistant tuberculosis (TB)&quot; refers to TB caused by an isolate of <em>Mycobacterium tuberculosis</em> that is resistant to one or more antituberculous drugs. Risk factors for drug-resistant TB are summarized in the table (<a href=\"image.htm?imageKey=ID%2F108729\" class=\"graphic graphic_table graphicRef108729 \">table 1</a>). (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The decision to start an empiric treatment regimen (including second-line drugs) for drug-resistant TB (pending drug susceptibility data) depends on the severity of clinical illness and the degree of suspicion for drug-resistant tuberculosis. Patient categories for whom an expanded empiric treatment regimen may be warranted are summarized above. An expanded empiric regimen usually consists of first-line drugs (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>) plus two or more additional drugs. Additional drugs include a fluoroquinolone, an injectable agent, <span class=\"nowrap\">and/or</span> another core second-line agent (<a href=\"image.htm?imageKey=ID%2F83653\" class=\"graphic graphic_table graphicRef83653 \">table 2</a>). Drug dosing is summarized in the tables (<a href=\"image.htm?imageKey=ID%2F55978\" class=\"graphic graphic_table graphicRef55978 \">table 3</a> and <a href=\"image.htm?imageKey=ID%2F66493\" class=\"graphic graphic_table graphicRef66493 \">table 4</a>). (See <a href=\"#H3816513493\" class=\"local\">'Empiric treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;monoresistant TB&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to a single antituberculous agent. The term &quot;poly-resistant TB&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to more than one antituberculous agent; the isolate may be resistant to either <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> or <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> but not both (<a href=\"image.htm?imageKey=ID%2F108731\" class=\"graphic graphic_table graphicRef108731 \">table 5</a>). The clinical approach to treatment of monoresistant TB or poly-resistant TB varies depending on the pattern of drug resistance. Treatment options are discussed above. (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above and <a href=\"#H7\" class=\"local\">'Treatment of monoresistant TB'</a> above and <a href=\"#H4285597129\" class=\"local\">'Treatment of poly-resistant TB'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;multidrug-resistant TB (MDR-TB)&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to both <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and possibly additional agents. Options for treatment of MDR-TB include the conventional MDR treatment regimen (total duration of therapy generally 20 to 26 months) or a shortened regimen (total duration of therapy 9 to 12 months). (See <a href=\"#H2\" class=\"local\">'Definitions'</a> above and <a href=\"#H12\" class=\"local\">'Treatment of multidrug-resistant TB'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For nonpregnant patients with MDR-TB (in the absence of extrapulmonary disease), with isolate known to be susceptible to fluoroquinolones and injectable antituberculous agents and no prior exposure to second-line agents for more than one month, we suggest treatment with a shortened MDR-TB regimen (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The shortened regimen consists of an intensive phase including daily administration of seven drugs for four months, followed by a continuation phase including daily administration of four drugs for five months. (See <a href=\"#H2244677597\" class=\"local\">'Shortened regimen'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients who do not meet criteria for the shortened MDR-TB regimen should be treated with the conventional regimen (<a href=\"image.htm?imageKey=ID%2F113634\" class=\"graphic graphic_figure graphicRef113634 \">figure 1</a> and <a href=\"image.htm?imageKey=ID%2F113635\" class=\"graphic graphic_table graphicRef113635 \">table 6</a>). The conventional regimen consists of an intensive phase including at least five drugs given for at least six months beyond sputum culture conversion (performed after two months of treatment), followed by a continuation phase including the drugs used during the intensive phase with the exception of the injectable agent, given for 18 to 24 months beyond sputum culture conversion. (See <a href=\"#H2784291708\" class=\"local\">'Conventional regimen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term &quot;extensively drug-resistant TB (XDR-TB)&quot; refers to TB caused by an isolate of <em>M. tuberculosis</em> that is resistant to at least <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, and fluoroquinolones as well as either aminoglycosides (<a href=\"topic.htm?path=amikacin-drug-information\" class=\"drug drug_general\">amikacin</a>, <a href=\"topic.htm?path=kanamycin-united-states-not-available-drug-information\" class=\"drug drug_general\">kanamycin</a>) or <a href=\"topic.htm?path=capreomycin-drug-information\" class=\"drug drug_general\">capreomycin</a> or both. Treatment of XDR-TB consists of an intensive phase including at least six drugs given for at least six months beyond sputum culture conversion, followed by a continuation phase including the drugs used during the intensive phase with the exception of the injectable agent, given for 18 to 24 months beyond culture conversion. (See <a href=\"#H4264781502\" class=\"local\">'Treatment of extensively drug-resistant TB'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In general, surgery for treatment of tuberculosis is most effective for patients with poor clinical response or intolerance to supervised medical therapy who have pulmonary disease that is amenable to complete resection. Consideration of surgery is warranted for management of MDR-TB in the setting of persistently positive cultures beyond four to six months of antituberculous therapy, presence of extensive patterns of drug resistance that are unlikely to be cured with antituberculous therapy alone, or presence of complications such as massive hemoptysis or persistent bronchopleural fistula. (See <a href=\"#H3057034217\" class=\"local\">'Role of surgery for MDR- or XDR-TB'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/1\" class=\"nounderline abstract_t\">Falzon D, Sch&uuml;nemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49.</a></li><li class=\"breakAll\">Curry International Tuberculosis Center. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition. CITC, Washington, DC 2016. http://www.currytbcenter.ucsf.edu/sites/default/files/tb_sg3_book.pdf (Accessed on July 12, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/3\" class=\"nounderline abstract_t\">Seaworth BJ, Griffith DE. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Microbiol Spectr 2017; 5.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/4\" class=\"nounderline abstract_t\">Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527.</a></li><li class=\"breakAll\">World Health Organization. Laboratory XDR-TB definitions. Meeting of the Global XDR TB Task Force. WHO, Geneva 2006.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/6\" class=\"nounderline abstract_t\">Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/7\" class=\"nounderline abstract_t\">Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579.</a></li><li class=\"breakAll\">World Health Organization. Global tuberculosis report 2015. WHO, Geneva 2015. http://www.who.int/tb/publications/global_report/en/ (Accessed on May 26, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/9\" class=\"nounderline abstract_t\">Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/10\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/11\" class=\"nounderline abstract_t\">Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/12\" class=\"nounderline abstract_t\">Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48:179.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/13\" class=\"nounderline abstract_t\">Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987; 136:1339.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/14\" class=\"nounderline abstract_t\">Reves R, Heilig CM, Tapy JM, et al. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuberc Lung Dis 2014; 18:571.</a></li><li class=\"breakAll\">World Health Organization. Treatment of tuberculosis: Guidelines --- 4th ed, Geneva 2010. whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf (Accessed on May 03, 2010).</li><li class=\"breakAll\">World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1 (Accessed on June 08, 2017).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/17\" class=\"nounderline abstract_t\">Schechter MC, Bizune D, Kagei M, et al. Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia. Clin Infect Dis 2017; 65:1862.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/18\" class=\"nounderline abstract_t\">Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 1:119.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/19\" class=\"nounderline abstract_t\">Stead WW, Dutt AK. Chemotherapy for tuberculosis today. Am Rev Respir Dis 1982; 125:94.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/20\" class=\"nounderline abstract_t\">Dutt AK, Jones L, Stead WW. Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin. Chest 1979; 75:441.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/21\" class=\"nounderline abstract_t\">Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/22\" class=\"nounderline abstract_t\">Franke MF, Becerra MC, Tierney DB, et al. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc 2015; 12:674.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/23\" class=\"nounderline abstract_t\">Schluger N, Ciotoli C, Cohen D, et al. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995; 151:1486.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/24\" class=\"nounderline abstract_t\">Bastard M, Sanchez-Padilla E, Hewison C, et al. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J Infect Dis 2015; 211:1607.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/25\" class=\"nounderline abstract_t\">Drugs for tuberculosis. Treat Guidel Med Lett 2012; 10:29.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/26\" class=\"nounderline abstract_t\">Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10:621.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/27\" class=\"nounderline abstract_t\">Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One 2013; 8:e55292.</a></li><li class=\"breakAll\">World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line antituberculosis drugs: Policy guidance. WHO, Geneva 2016. http://www.who.int/tb/WHOPolicyStatementSLLPA.pdf?ua=1 (Accessed on May 23, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/29\" class=\"nounderline abstract_t\">Dowdy DW, Theron G, Tornheim JA, et al. Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. Clin Infect Dis 2017; 65:1206.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/30\" class=\"nounderline abstract_t\">Sotgiu G, Tiberi S, D'Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387:2486.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/31\" class=\"nounderline abstract_t\">Ahmad Khan F, Gelmanova IY, Franke MF, et al. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB. Clin Infect Dis 2016; 63:214.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/32\" class=\"nounderline abstract_t\">Aung KJ, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18:1180.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/33\" class=\"nounderline abstract_t\">Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis 2005; 40:1689.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/34\" class=\"nounderline abstract_t\">Palacios E, Dallman R, Mu&ntilde;oz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009; 48:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/35\" class=\"nounderline abstract_t\">Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16:717.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/36\" class=\"nounderline abstract_t\">Heysell SK, Moore JL, Peloquin CA, et al. Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014. Tuberc Respir Dis (Seoul) 2015; 78:78.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/37\" class=\"nounderline abstract_t\">Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/38\" class=\"nounderline abstract_t\">Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/39\" class=\"nounderline abstract_t\">Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/40\" class=\"nounderline abstract_t\">Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40:968.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/41\" class=\"nounderline abstract_t\">Tahao&#287;lu K, T&ouml;r&uuml;n T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/42\" class=\"nounderline abstract_t\">Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/43\" class=\"nounderline abstract_t\">Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/44\" class=\"nounderline abstract_t\">Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/45\" class=\"nounderline abstract_t\">Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014; 20:812.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/46\" class=\"nounderline abstract_t\">Salinas JL, Armstrong LR, Silk BJ, et al. Factors Associated With All-Cause Mortality Among Patients With Multidrug-Resistant Tuberculosis-United States, 1993-2013. Clin Infect Dis 2017; 65:1924.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/47\" class=\"nounderline abstract_t\">Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:563.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/48\" class=\"nounderline abstract_t\">Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51:6.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/49\" class=\"nounderline abstract_t\">Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/50\" class=\"nounderline abstract_t\">Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42:169.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/51\" class=\"nounderline abstract_t\">Shenoi SV, Brooks RP, Barbour R, et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012; 7:e31786.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/52\" class=\"nounderline abstract_t\">Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/53\" class=\"nounderline abstract_t\">Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45:1290.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/54\" class=\"nounderline abstract_t\">Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/55\" class=\"nounderline abstract_t\">Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300:2153.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/56\" class=\"nounderline abstract_t\">Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/57\" class=\"nounderline abstract_t\">Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012; 16:90.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/58\" class=\"nounderline abstract_t\">Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/59\" class=\"nounderline abstract_t\">Padayatchi N, Abdool Karim SS, Naidoo K, et al. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis 2014; 18:147.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/60\" class=\"nounderline abstract_t\">McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 Suppl 1:S63.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/61\" class=\"nounderline abstract_t\">Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 2009; 22:11.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/62\" class=\"nounderline abstract_t\">Fox GJ, Mitnick CD, Benedetti A, et al. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis 2016; 62:887.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/63\" class=\"nounderline abstract_t\">Sung SW, Kang CH, Kim YT, et al. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. Eur J Cardiothorac Surg 1999; 16:187.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/64\" class=\"nounderline abstract_t\">Souilamas R, Riquet M, Barthes FP, et al. Surgical treatment of active and sequelar forms of pulmonary tuberculosis. Ann Thorac Surg 2001; 71:443.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/65\" class=\"nounderline abstract_t\">Pomerantz BJ, Cleveland JC Jr, Olson HK, Pomerantz M. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001; 121:448.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/66\" class=\"nounderline abstract_t\">Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007; 62:416.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/67\" class=\"nounderline abstract_t\">Park SK, Kim JH, Kang H, et al. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2009; 13:170.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/68\" class=\"nounderline abstract_t\">Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006; 12:179.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/69\" class=\"nounderline abstract_t\">Dravniece G, Cain KP, Holtz TH, et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J 2009; 34:180.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/70\" class=\"nounderline abstract_t\">van Leuven M, De Groot M, Shean KP, et al. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63:1368.</a></li><li class=\"breakAll\">ERS/WHO. TB Consilium. www.tbconsilium.org (Accessed on April 28, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults/abstract/72\" class=\"nounderline abstract_t\">Blasi F, Dara M, van der Werf MJ, Migliori GB. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41:491.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8028 Version 62.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3118802\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITIONS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL PRESENTATION</a></li><li><a href=\"#H3816513493\" id=\"outline-link-H3816513493\">EMPIRIC TREATMENT</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">TREATMENT OF MONORESISTANT TB</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Isoniazid monoresistance</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Monoresistance to other agents</a></li></ul></li><li><a href=\"#H4285597129\" id=\"outline-link-H4285597129\">TREATMENT OF POLY-RESISTANT TB</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">TREATMENT OF MULTIDRUG-RESISTANT TB</a><ul><li><a href=\"#H1101222462\" id=\"outline-link-H1101222462\">Clinical approach</a><ul><li><a href=\"#H1543255266\" id=\"outline-link-H1543255266\">- Nonpregnant adults</a><ul><li><a href=\"#H2010335105\" id=\"outline-link-H2010335105\">General principles</a></li><li><a href=\"#H333119688\" id=\"outline-link-H333119688\">Regimens</a><ul><li><a href=\"#H2784291708\" id=\"outline-link-H2784291708\">- Conventional regimen</a></li><li><a href=\"#H2244677597\" id=\"outline-link-H2244677597\">- Shortened regimen</a></li></ul></li><li><a href=\"#H1802415633\" id=\"outline-link-H1802415633\">Monitoring</a></li></ul></li><li><a href=\"#H3138981029\" id=\"outline-link-H3138981029\">- Children</a></li><li><a href=\"#H3145613949\" id=\"outline-link-H3145613949\">- Pregnant women</a></li><li><a href=\"#H3115947\" id=\"outline-link-H3115947\">- Treatment failure</a></li></ul></li><li><a href=\"#H26\" id=\"outline-link-H26\">Outcomes</a></li></ul></li><li><a href=\"#H4264781502\" id=\"outline-link-H4264781502\">TREATMENT OF EXTENSIVELY DRUG-RESISTANT TB</a><ul><li><a href=\"#H1915663590\" id=\"outline-link-H1915663590\">Clinical approach</a></li><li><a href=\"#H572632094\" id=\"outline-link-H572632094\">Outcomes</a></li></ul></li><li><a href=\"#H2764093192\" id=\"outline-link-H2764093192\">HIV-INFECTED PATIENTS</a></li><li><a href=\"#H3057034217\" id=\"outline-link-H3057034217\">ROLE OF SURGERY FOR MDR- OR XDR-TB</a></li><li><a href=\"#H3445015247\" id=\"outline-link-H3445015247\">RESOURCES FOR EXPERT GUIDANCE</a></li><li><a href=\"#H786782680\" id=\"outline-link-H786782680\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H3118802\" id=\"outline-link-H3118802\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8028|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/113634\" class=\"graphic graphic_figure\">- Building a conventional regimen for MDR-TB</a></li></ul></li><li><div id=\"ID/8028|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/108729\" class=\"graphic graphic_table\">- Risk factors for drug-resistant tuberculosis</a></li><li><a href=\"image.htm?imageKey=ID/83653\" class=\"graphic graphic_table\">- Categories of antituberculous agents</a></li><li><a href=\"image.htm?imageKey=ID/55978\" class=\"graphic graphic_table\">- First-line TB drugs: Dosing</a></li><li><a href=\"image.htm?imageKey=ID/66493\" class=\"graphic graphic_table\">- Second-line TB drugs: Dosing</a></li><li><a href=\"image.htm?imageKey=ID/108731\" class=\"graphic graphic_table\">- Rx poly-resistant tuberculosis</a></li><li><a href=\"image.htm?imageKey=ID/113635\" class=\"graphic graphic_table\">- Conventional regimens for MDR/XDR-TB</a></li><li><a href=\"image.htm?imageKey=ID/53563\" class=\"graphic graphic_table\">- Adverse effects - TB and HIV medicines</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">Adherence to tuberculosis treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">Antituberculous drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Diagnosis of pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-molecular-mechanisms-of-drug-resistant-tuberculosis\" class=\"medical medical_review\">Epidemiology and molecular mechanisms of drug-resistant tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-extensively-drug-resistant-tuberculosis\" class=\"medical medical_review\">Epidemiology of extensively drug-resistant tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mycobacterium-bovis\" class=\"medical medical_review\">Mycobacterium bovis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-disease-in-children\" class=\"medical medical_review\">Tuberculosis disease in children</a></li></ul></div></div>","javascript":null}